Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Treasury Shares: 2015-2025

Historic Treasury Shares for Voyager Therapeutics (VYGR) over the last 10 years, with Sep 2025 value amounting to $2.5 million.

  • Voyager Therapeutics' Treasury Shares rose 56.68% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 56.68%. This contributed to the annual value of $1.6 million for FY2024, which is 20.35% up from last year.
  • Voyager Therapeutics' Treasury Shares amounted to $2.5 million in Q3 2025, which was down 7.07% from $2.7 million recorded in Q2 2025.
  • Over the past 5 years, Voyager Therapeutics' Treasury Shares peaked at $2.8 million during Q1 2025, and registered a low of $806,379 during Q4 2021.
  • For the 3-year period, Voyager Therapeutics' Treasury Shares averaged around $1.8 million, with its median value being $1.6 million (2024).
  • In the last 5 years, Voyager Therapeutics' Treasury Shares soared by 115.05% in 2021 and then slumped by 31.70% in 2022.
  • Quarterly analysis of 5 years shows Voyager Therapeutics' Treasury Shares stood at $806,379 in 2021, then spiked by 37.97% to $1.1 million in 2022, then climbed by 23.22% to $1.4 million in 2023, then grew by 20.35% to $1.6 million in 2024, then spiked by 56.68% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q3 2025, $2.7 million for Q2 2025, and $2.8 million during Q1 2025.